KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other financing activities (2020 - 2025)

Royalty Pharma (RPRX) has disclosed Other financing activities for 5 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • Quarterly Other financing activities rose 114.15% to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.7 million through Dec 2025, up 89.85% year-over-year, with the annual reading at $16.6 million for FY2025, 283.5% up from the prior year.
  • Other financing activities hit $3.0 million in Q4 2025 for Royalty Pharma, down from $13.5 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $13.5 million in Q3 2025 to a low of -$21.3 million in Q4 2024.
  • Historically, Other financing activities has averaged $1.9 million across 4 years, with a median of $3.0 million in 2025.
  • Biggest five-year swings in Other financing activities: surged 430.46% in 2021 and later tumbled 1437.22% in 2024.
  • Year by year, Other financing activities stood at $801000.0 in 2021, then soared by 99.25% to $1.6 million in 2023, then crashed by 1437.22% to -$21.3 million in 2024, then skyrocketed by 114.15% to $3.0 million in 2025.
  • Business Quant data shows Other financing activities for RPRX at $3.0 million in Q4 2025, $13.5 million in Q3 2025, and -$21.3 million in Q4 2024.